🟢 10x Genomics is trading 10.44% up today on positive melanoma-vaccine results

10x Genomics is trading 10.44% up at $61.44 as biotechnology shares rally following positive Phase 3 melanoma-vaccine results from Moderna and Merck.

• The treatment met goals for reducing melanoma recurrence and preventing its spread.
• The results lifted sentiment toward mRNA technology and drug-development platforms.
• No company-specific announcement from 10x Genomics was identified on August 19, 2026; the move is best explained by sector-wide biotechnology enthusiasm.